iShares 0 3 Month Treasury Bond ETF vs Tilray Brands Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B), while Tilray Brands Inc trades at $3.61 (market cap $530.54M). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 215.6× Tilray Brands Inc's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and Tilray Brands Inc for 31 Days on average.
| SGOV | TLRY | |
|---|---|---|
Market Cap | $114.40B | $530.54M |
Volume | 18,879,081 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $21.00 |
52-Week Low | $100.28 | $3.57 |
Typical Hold Time | 50 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill holdings. The ETF shows bearish technical signals with 17 sell indicators versus 4 buy signals, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026. The fund continues its consistent dividend payments with recent distributions of $0.30-$0.31 per share.
SGOV provides exposure to ultra-short-term Treasury securities, offering stability amid bond market volatility. The ETF faces headwinds from rising interest rates but benefits from flight-to-quality flows. Key risks include interest rate sensitivity and potential yield compression if Fed policy shifts dovishly. Current technical weakness may present entry opportunities for income-focused investors seeking capital preservation.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →